ReportsnReports – VEGF Inhibition: Therapy-Indicating and Prognostic Biomarkers, 2011
Upcoming SlideShare
Loading in...5
×
 

ReportsnReports – VEGF Inhibition: Therapy-Indicating and Prognostic Biomarkers, 2011

on

  • 384 views

Vascular Endothelial Growth Factor (VEGF), which plays an important role in angiogenesis, has been extensively studied and over-expression is seen in many cancers. Today, VEGF is targeted using ...

Vascular Endothelial Growth Factor (VEGF), which plays an important role in angiogenesis, has been extensively studied and over-expression is seen in many cancers. Today, VEGF is targeted using antibodies and tyrosine kinase inhibitors, and antiangiogenic therapy is a standard treatment for many cancers, including colorectal and non-small cell lung cancer.

Statistics

Views

Total Views
384
Views on SlideShare
384
Embed Views
0

Actions

Likes
0
Downloads
5
Comments
0

0 Embeds 0

No embeds

Accessibility

Upload Details

Uploaded via as Adobe PDF

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

ReportsnReports – VEGF Inhibition: Therapy-Indicating and Prognostic Biomarkers, 2011 ReportsnReports – VEGF Inhibition: Therapy-Indicating and Prognostic Biomarkers, 2011 Document Transcript

  • VEGF Inhibition: Therapy-Indicating and Prognostic Biomarkers, 2011ReportsnReports.com adds Biopharm Reports Publishers Market Research Report “VEGFInhibition: Therapy-Indicating and Prognostic Biomarkers, 2011’’ to its store.Vascular Endothelial Growth Factor (VEGF), which plays an important role in angiogenesis,has been extensively studied and over-expression is seen in many cancers. Today, VEGF istargeted using antibodies and tyrosine kinase inhibitors, and antiangiogenic therapy is astandard treatment for many cancers, including colorectal and non-small cell lung cancer.While VEGF inhibitors such as bevacizumab (Avastin®) provide valuable treatment options,these benefits are not seen in all patients and cancer types. Today, there is an urgent needfor predictive biomarkers to enable those patients most likely to benefit from VEGFinhibition, to be identified. This report provides a review of findings to date on biomarkersassociated with the use bevacizumab (Avastin®); both therapy-indicating and prognostic.Browse: VEGF Biomarkers 2011The identification of therapy-indicating and prognostic biomarkers relating to antiangiogenictherapy is in its early stages, however important advances have been made. This reportidentifies the latest findings on ten different cancers and includes an evaluation of candidatebiomarkers as a basis for interpreting patient outcomes according to RECIST criteria, andevaluates existing bevacizumab-containing treatments and drug combinations.Key content: A comprehensive review of clinical studies that have identified biomarkers that are either therapy-indicating in respect of bevacizumab (Avastin®) or indicative of patient prognosis Biomarkers identified or further evaluated in the last three years, up until October 2011. From a background of extensive research on bevacizumab (Avastin®) and VEGF-related biomarkers, the most important findings have been identified for their significance and value to patients and in designing clinical trials Covering more than ten cancers including colorectal, ovarian, renal, breast, pancreatic, prostate, lung and liver cancers Findings based on clinical trial findings including patient numbers, statistics and RECIST criteria Studies indicate drug type associations together with comparative therapies Descriptions and explanation of all biomarkers identified roteins, genotypes, imaging etc) Biomarker associations are categorised according to three broad criteria, namely “positive-therapy-indicating” (response, improved response, improved outcome or prognosis), “non-therapy-indicating” (no differences in tumour response, outcome or prognosis) and “negative-therapy-indicating” (adverse events, poor outcome or prognosis)
  • Table of ContentsExecutive SummaryChapter-1: Background1.1. VEGF Inhibition1.2. Bevacizumab1.3. Biomarkers1.4. This ReportChapter-2: Colorectal Cancer: Candidate Biomarkers identified in Patientsreceiving Bevacizumab-containing TherapiesSummary2.1. Introduction2.2. Glycoprotein2.3. Protein2.4. Protein2.5. Cells2.6. Genetic2.7. Physical2.8. Genetic2.9. Protein2.10. Proteins2.11. Proteins and Genetic2.12. Image2.13. Proteins2.14. ProteinChapter-3: Breast Cancer: Candidate Biomarkers identified in Patients receivingBevacizumab-containing TherapiesSummary3.1. Introduction3.2. Protein3.3. Protein3.4. Protein3.5. Protein3.6. Protein3.7. Genetic3.8. ProteinChapter-4: Renal Cancer: Candidate Biomarkers identified in Patients receivingBevacizumab-containing TherapiesSummary4.1. Introduction4.2. Image4.3. Protein4.4. Physical4.5. Protein4.6. Body Characteristic
  • Chapter-5: Ovarian Cancer: Candidate Biomarkers identified in Patients receivingBevacizumab-containing TherapiesSummary5.1. Introduction5.2. Proteins5.3. Proteins5.4. Proteins5.5. ProteinsChapter-6: Lung Cancer: Candidate Biomarkers identified in Patients receivingBevacizumab-containing TherapiesSummary6.1. Introduction6.2. Physical Parameter6.3. Protein6.4. Genetic6.5. ProteinChapter-7: Liver Cancer: Candidate Biomarkers identified in Patients receivingBevacizumab-containing TherapiesSummary7.1. Introduction7.2. Protein7.3. ImageChapter-8: Other Cancers: Candidate Biomarkers identified in Patients receivingBevacizumab-containing TherapiesSummary8.1. Introduction8.2. Proteins8.3. Proteins8.4. Protein8.5. Protein8.6. Physical8.7. Physical8.8. PhysicalChapter-9: Discussion9.1. Overview9.2. Colorectal Cancer9.3. Breast Cancer:9.4. Renal Cancer:9.5. Ovarian Cancer9.6. Lung Cancer9.7. Liver Cancer9.8. Other Cancers9.9. Conclusions
  • List of TablesTable 2.1: Candidates biomarkers identified in colorectal cancer patients receivingbevacizumab-containing therapies (cancer, biomarker, biomarker type, drug therapies)Table 3.1: Candidates biomarkers identified in breast cancer patients receivingbevacizumab-containing therapies (cancer, biomarker, biomarker type, drug therapies)Table 4.1: Candidates biomarkers identified in renal cancer patients receiving bevacizumab-containing therapies (cancer, biomarker, biomarker type, drug therapies)Table 5.1: Candidates biomarkers identified in ovarian cancer patients receivingbevacizumab-containing therapies (cancer, biomarker, biomarker type, drug therapies)Table 6.1: Candidates biomarkers identified in lung cancer patients receiving bevacizumab-containing therapies (cancer, biomarker, biomarker type, drug therapies)Table 7.1: Candidates biomarkers identified in liver cancer patients receiving bevacizumab-containing therapies (cancer, biomarker, biomarker type, drug therapies)Table 8.1: Candidates biomarkers identified in other cancer patients receiving bevacizumab-containing therapies (cancer, biomarker, biomarker type, drug therapies)Table 9.1: Protein candidate biomarkers identified in cancer patients receiving bevacizumab-containing therapies (cancer, biomarker, biomarker type, drug therapies)Table 9.2: Genetic candidate biomarkers identified in cancer patients receivingbevacizumab-containing therapies (cancer, biomarker, biomarker type, drug therapies)Table 9.3: Image-based candidate biomarkers identified in cancer patients receivingbevacizumab-containing therapies (cancer, biomarker, biomarker type, drug therapies)Table 9.4: Other candidate biomarkers identified in cancer patients receiving bevacizumab-containing therapies (cancer, biomarker, biomarker type, drug therapies)List of FiguresFigure 9.1: Candidate biomarkers types identified in cancer patients receiving bevacizumab-containing therapiesFigure 9.2: Cancer types evaluated for biomarkers identified in cancer patients receivingbevacizumab-containing therapiesFigure 9.3: Author countries (identified in this report) of cancers evaluated for biomarkersidentified in cancer patients receiving bevacizumab-containing therapiesLatest Market Research Reports: North American Fire and Life Safety Market Brazilian Industrial Protective Footwear Market Drug Repositioning: New Technologies, Business Models & Strategies for Successful Development On-Trade Alcoholic Drinking Trends: Differentiating consumer on-trade drinking occasions to capitalize on value generating opportunities Recycling Equipment Market in Singapore – Singapore recycling equipment marketAbout Us:ReportsnReports is an online library of over 75,000 market research reports and in-depthmarket research studies & analysis of over 5000 micro markets. We provide 24/7 online andoffline support to our customers. Get in touch with us for your needs of market researchreports.Follow us on Twitter: http://twitter.com/marketsreportsOur Facebook Page: http://www.facebook.com/pages/ReportsnReports/191441427571689
  • Contact:Mr. Priyank7557 Rambler road,Suite 727, Dallas, TX 75231Tel: + 1 888 391 5441E-mail: sales@reportsandreports.comhttp://www.reportsnreports.comVisit Our Blog : Market Research Reports